期刊
CURRENT OPINION IN RHEUMATOLOGY
卷 26, 期 6, 页码 607-614出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0000000000000110
关键词
extracellular matrix; fibrosis; myofibroblasts; senescence; stiffness
类别
资金
- National Institute of Arthritis and Musculoskeletal and Skin Diseases [K08AR062592, R01AR42309]
- Scleroderma Foundation
- Biogen
- Department of Defense
Purpose of review To summarize the recent advances in understanding the novel cytokine pathways, intracellular signaling molecules, cell-fate decisions, cellular aging and senescence, and the cross-talk of effector cells and the extracellular matrix (ECM) in the pathogenesis of systemic sclerosis (SSc) fibrosis. Recent findings Studies from the animal models and human beings implicate novel molecular pathways such as Wnts, the chemokines, chemokine (C-X-C motif) ligand 4 and chemokine (C-C motif) ligand 2, and the lipid mediators lysophosphatidic acid and sphingosine-1-phosphate in the pathogenesis of SSc. These signals, coupled with the mesenchymal cell-fate decisions, contribute to aberrant fibroblast activation and myofibroblast accumulation. The resulting deposition and remodeling of ECM alters the biomechanical environment, and leads to further cross-talk of mechanical signals with biochemical mediators such as focal adhesion kinase, integrin signaling, and Yes-associated protein-transcriptional coactivator with PDZ-binding motif signaling pathways. Summary Progress in understanding the cellular, molecular, and biomechanical regulators of fibrosis has led to the identification of novel targets for interrupting the fibrotic process in SSc. Efforts to antagonize cytokine pathways, affect mesenchymal cell fates, attenuate senescence, and clear activated myofibroblasts, along with modifying the ECM mechanical environment, may ultimately lead to effective therapies in SSc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据